entity

BBB transcytosis

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BBB transcytosis: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections

1Hypotheses

2Analyses

0Outgoing

1Incoming

0Experiments

2Debates

No AI portrait yet

Outgoing (0)

Target	Relation	Type	Str
No outgoing edges

Incoming (1)

Source	Relation	Type	Str
TfR	mediates	protein	0.70

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytos	0.550	drug delivery	Can IGFBPL1 therapeutics effectively cro

Mentioning Analyses (2)

Scientific analyses that reference this entity

How do synthetic EVs achieve brain-specific targeting while avoiding reticuloend

drug delivery | 2026-04-15 | 0 hypotheses

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

All participants identified brain delivery as a critical barrier, but no mechani

closed · Rounds: 4 · Score: 0.50 · 2026-04-16

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

Related Research

Hypotheses and analyses mentioning BBB transcytosis in their description or question text

No additional research found